Drug intelligence / Profile preview

BJTJ-0003

Development stage: Unknown
Lead developer: Beijing Tuojie Biomedical Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

BJTJ-0003 is a bio-fermented monoclonal antibody under development by Beijing Tuobixi Pharmaceutical (also known as Beijing Tuojie Biomedical Technology) for the treatment of thrombosis. The drug is currently in Phase II clinical development in collaboration with Meiji. Beijing Tuobixi Pharmaceutical is a biotechnology company based in Beijing, China, that focuses on the research and development of therapeutic proteins and peptide biopharmaceuticals for chronic diseases, including cardiovascular and metabolic conditions.

Beyond the preview

Go deeper on BJTJ-0003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BJTJ-0003.

Explore the full profile